Results of the multivariable analysis for CEBPAbi vs CEBPAsm
| . | OS (HR) . | P . | 95% CI . | EFS (HR) . | P . | 95% CI . | CR1 (OR) . | P . | 95% CI . |
|---|---|---|---|---|---|---|---|---|---|
| Intermediate karyotype | 1 | 1 | 1 | ||||||
| Favorable karyotype | 0.427 | <.001 | (0.35-0.52) | 0.400 | <.001 | (0.34-0.47) | 3.063 | <.001 | (2.07-4.54) |
| Adverse karyotype* | 1.858 | <.001 | (1.68-2.05) | 1.633 | <.001 | (1.49-1.79) | 0.477 | <.001 | (0.40-0.57) |
| Age | 1.032 | <.001 | (1.03-1.04) | 1.023 | <.001 | (1.02-1.03) | 0.948 | <.001 | (0.94-0.95) |
| Log10 WBC | 1.155 | <.001 | (1.08-1.24) | 1.228 | <.001 | (1.15-1.31) | 0.754 | <.001 | (0.66-0.87) |
| De novo AML | 1 | 1 | 1 | ||||||
| sAML | 1.086 | .131 | (0.98-1.21) | 1.069 | .196 | (0.97-1.18) | 0.733 | .002 | (0.60-0.90) |
| tAML | 1.386 | <.001 | (1.20-1.60) | 1.098 | .186 | (0.96-1.26) | 0.691 | .009 | (0.52-0.91) |
| No FLT3-ITDmut | 1 | 1 | 1 | ||||||
| FLT3-ITDmut | 1.206 | <.001 | (1.09-1.33) | 1.242 | <.001 | (1.14-1.36) | 1.017 | .870 | (0.83-1.25) |
| No NPM1mut | 1 | 1 | 1 | ||||||
| NPM1mut | 0.629 | <.001 | (0.57-0.69) | 0.535 | <.001 | (0.49-0.59) | 2.127 | <.001 | (1.75-2.59) |
| CEBPAwt | 1 | 1 | 1 | ||||||
| CEBPAbi | 0.510 | <.001 | (0.39-0.67) | 0.534 | <.001 | (0.42-0.68) | 6.328 | <.001 | (2.73-14.67) |
| CEBPAsm | 0.825 | .122 | (0.65-1.05) | 0.746 | .011 | (0.56-0.94) | 1.117 | .644 | (0.70-1.78) |
| No allo-HSCT in CR1 | 1 | 1 | 1 | ||||||
| Allo-HSCT in CR1 | 0.773 | <.001 | (0.69-0.87) | 0.630 | <.001 | (0.56-0.79) | — | — | — |
| . | OS (HR) . | P . | 95% CI . | EFS (HR) . | P . | 95% CI . | CR1 (OR) . | P . | 95% CI . |
|---|---|---|---|---|---|---|---|---|---|
| Intermediate karyotype | 1 | 1 | 1 | ||||||
| Favorable karyotype | 0.427 | <.001 | (0.35-0.52) | 0.400 | <.001 | (0.34-0.47) | 3.063 | <.001 | (2.07-4.54) |
| Adverse karyotype* | 1.858 | <.001 | (1.68-2.05) | 1.633 | <.001 | (1.49-1.79) | 0.477 | <.001 | (0.40-0.57) |
| Age | 1.032 | <.001 | (1.03-1.04) | 1.023 | <.001 | (1.02-1.03) | 0.948 | <.001 | (0.94-0.95) |
| Log10 WBC | 1.155 | <.001 | (1.08-1.24) | 1.228 | <.001 | (1.15-1.31) | 0.754 | <.001 | (0.66-0.87) |
| De novo AML | 1 | 1 | 1 | ||||||
| sAML | 1.086 | .131 | (0.98-1.21) | 1.069 | .196 | (0.97-1.18) | 0.733 | .002 | (0.60-0.90) |
| tAML | 1.386 | <.001 | (1.20-1.60) | 1.098 | .186 | (0.96-1.26) | 0.691 | .009 | (0.52-0.91) |
| No FLT3-ITDmut | 1 | 1 | 1 | ||||||
| FLT3-ITDmut | 1.206 | <.001 | (1.09-1.33) | 1.242 | <.001 | (1.14-1.36) | 1.017 | .870 | (0.83-1.25) |
| No NPM1mut | 1 | 1 | 1 | ||||||
| NPM1mut | 0.629 | <.001 | (0.57-0.69) | 0.535 | <.001 | (0.49-0.59) | 2.127 | <.001 | (1.75-2.59) |
| CEBPAwt | 1 | 1 | 1 | ||||||
| CEBPAbi | 0.510 | <.001 | (0.39-0.67) | 0.534 | <.001 | (0.42-0.68) | 6.328 | <.001 | (2.73-14.67) |
| CEBPAsm | 0.825 | .122 | (0.65-1.05) | 0.746 | .011 | (0.56-0.94) | 1.117 | .644 | (0.70-1.78) |
| No allo-HSCT in CR1 | 1 | 1 | 1 | ||||||
| Allo-HSCT in CR1 | 0.773 | <.001 | (0.69-0.87) | 0.630 | <.001 | (0.56-0.79) | — | — | — |
The multivariable analysis performed includes the different study regimens as strata.
Adverse karyotype according to ELN 2017.